At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
|Articles|May 7, 2012
Patrick Geraghty Discusses the Relationship Between Health Plans and its Membership
Mr. Geraghty points out a variety of ways to engage a health plan's members.
Advertisement
Patrick Geraghty, Chairman & CEO, Blue Cross Blue Shield of Florida, states that community outreach helps a great deal in building trust with Florida Blue's membership. Engaging the consumers personally with community service and online tools will also strengthen the relationship a health plan has with its members.
Advertisement
Related to this article
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
On the opening day of CHEST 2026, the organization's flagship journal highlights a trio of key papers with practice-changing results for COPD.
Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
Advertisement
Advertisement
Trending on AJMC
1
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
2
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
3
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
4
CHEST: The Face of Lung Cancer Has Changed, but Screening, Care Have Gaps
5